By a staff reporter : GLENMARK LIFE SCIENCE LTD.
IPO - Review
Glenmark Life Science (GLSL) is a leading developer and manufacturer of
select high value, non-commoditized active pharmaceutical ingredients
(“APIs”) in chronic therapeutic areas, including cardiovascular disease
(“CVS ”), central nervous system disease (“CNS”), pain management and
diabetes. It is a wholly-owned subsidiary of Glenmark Pharmaceuticals
Limited, a research - oriented, innovation led, global pharmaceutical
company. Glenmark launched the API manufacturing business by setting
up a manufacturing facility in Kurkumbh in the state of Maharashtra,
India and focused on growing this business over the next 18 years. In 2019,
the API manufacturing business of Glenmark was sold and spun off into
a separate company as part of a broader reorganization designed to
place GLSL on an accelerated trajectory to attain its objectives in three
different verticals, with GLSL focusing on the API business. Post Spinoff,
GLSL operate as an independent, professionally-managed global API
business. Post issue Promoter shareholding will be 82.84%
for subscribe in IPO please contact 9831200699
Source : Eureka
/anm-english/media/agency_attachments/AtBG5e3MoE629QYzhZen.png)
/ )
/anm-english/media/post_banners/AmfjclB7EZz5zvmb02Gq.jpg)